PT110070A - Novos compostos espiro-lactâmicos, processo e seus usos - Google Patents

Novos compostos espiro-lactâmicos, processo e seus usos

Info

Publication number
PT110070A
PT110070A PT11007017A PT11007017A PT110070A PT 110070 A PT110070 A PT 110070A PT 11007017 A PT11007017 A PT 11007017A PT 11007017 A PT11007017 A PT 11007017A PT 110070 A PT110070 A PT 110070A
Authority
PT
Portugal
Prior art keywords
compounds
lactic
new
disclosure
spiro
Prior art date
Application number
PT11007017A
Other languages
English (en)
Inventor
Miguel Prudêncio Pignatelli Rui
Margarida Vasconcelos Dias De Pinho E Melo Teresa
C Suzano Santos Bruna
Bártolo Inês
Eduardo Moura Dos Santos Da Costa Taveira Nuno
Original Assignee
Inst De Medicina Molecular
Univ De Coimbra
Egas Moniz Coop De Ensino Superior Crl
Faculdade De Farmacia Da Univ De Lisboa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst De Medicina Molecular, Univ De Coimbra, Egas Moniz Coop De Ensino Superior Crl, Faculdade De Farmacia Da Univ De Lisboa filed Critical Inst De Medicina Molecular
Priority to PT11007017A priority Critical patent/PT110070A/pt
Priority to US16/613,061 priority patent/US11666559B2/en
Priority to EP18734290.2A priority patent/EP3625238A1/en
Priority to PCT/IB2018/053357 priority patent/WO2018207165A1/en
Publication of PT110070A publication Critical patent/PT110070A/pt
Priority to US18/299,404 priority patent/US20230285366A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/90Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring further condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20Spiro-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A PRESENTE DIVULGAÇÃO REFERE-SE A UMA NOVA CLASSE DE AGENTES ANTIMICROBIANOS, EM PARTICULAR, ESTA DIVULGAÇÃO FORNECE A IDENTIFICAÇÃO E CARACTERIZAÇÃO DE NOVOS COMPOSTOS ESPIROLACTÂMICOS COMO AGENTES ANTI-VIH/SIDA E ANTIMALÁRICOS. ALÉM DISSO, ESTA DIVULGAÇÃO TAMBÉM FORNECE A PREPARAÇÃO DE ÁCIDOS ESPIRO-Β-PENICILÂNICOS, QUE PROVARAM SER INIBIDORES POTENTES DO VIH.
PT11007017A 2017-05-12 2017-05-12 Novos compostos espiro-lactâmicos, processo e seus usos PT110070A (pt)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PT11007017A PT110070A (pt) 2017-05-12 2017-05-12 Novos compostos espiro-lactâmicos, processo e seus usos
US16/613,061 US11666559B2 (en) 2017-05-12 2018-05-14 Spiro-lactam compounds, process and uses thereof
EP18734290.2A EP3625238A1 (en) 2017-05-12 2018-05-14 Novel spiro-lactam compounds, process and uses thereof
PCT/IB2018/053357 WO2018207165A1 (en) 2017-05-12 2018-05-14 Novel spiro-lactam compounds, process and uses thereof
US18/299,404 US20230285366A1 (en) 2017-05-12 2023-04-12 Spiro-lactam compounds, process and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT11007017A PT110070A (pt) 2017-05-12 2017-05-12 Novos compostos espiro-lactâmicos, processo e seus usos

Publications (1)

Publication Number Publication Date
PT110070A true PT110070A (pt) 2018-11-12

Family

ID=62749118

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11007017A PT110070A (pt) 2017-05-12 2017-05-12 Novos compostos espiro-lactâmicos, processo e seus usos

Country Status (4)

Country Link
US (2) US11666559B2 (pt)
EP (1) EP3625238A1 (pt)
PT (1) PT110070A (pt)
WO (1) WO2018207165A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111514299A (zh) * 2020-04-29 2020-08-11 广州中医药大学科技产业园有限公司 一种用于防治肺炎的组合物及其在制备用于防治肺炎的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289692A (en) 1976-01-21 1977-07-27 Sankyo Co Ltd Penicillin and cephalosporin derivatives and preparation thereof

Also Published As

Publication number Publication date
US11666559B2 (en) 2023-06-06
US20230285366A1 (en) 2023-09-14
US20200352916A1 (en) 2020-11-12
WO2018207165A1 (en) 2018-11-15
EP3625238A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
MD3445850T2 (ro) Metode de obținere a ARN monocatenar
CL2020000946A1 (es) Métodos y composiciones para la producción de trifosfato de nucleosido y ácido ribonucleico
CO2017011851A2 (es) Compuestos novedosos
BR112018068682A2 (pt) ?artigo, e, método para produção de um artigo?
MA39727A (fr) Compositions antimicrobiennes pour végétaux
GT201700099A (es) 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1
ECSP15018618A (es) Inhibidores no nucleósidos de la transcriptasa inversa
AU2016263598A8 (en) Methods and kits for treating depression
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
DOP2018000266A (es) 1H-Pirazolo[4,3-b]piridinas como inhibidores de PDE1
MX2019007738A (es) Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos.
MX370628B (es) Composiciones y metodos para tratar las espinillas.
PH12018501362A1 (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
CO2018003739A2 (es) Sales de un inhibidor de pim quinasa
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
MY176057A (en) Use of neutralizing agent in olefin or styrene production
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
CO2019013655A2 (es) Compuestos heterocíclicos bicíclicos sustituidos como inhibidores de la nadph oxidasa
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
IN2013CH04023A (pt)
PH12020550983A1 (en) Process for the preparation of an amino-pyrimidine and intermediates thereof
WO2016060935A3 (en) Compositions and methods of improving the digestibility of animal feed
PH12019500479A1 (en) Compositions for treating dementia

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 20180925